Core Business and Technology Platform

The central focus of Q Therapeutics' work is the development of a unique glial progenitor cell technology platform. Glial cells, which make up approximately 50% of the brain???s mass, are non-neuronal cells that are critical for providing support, protection, and a healthy cellular environment for neurons. In many neurodegenerative conditions and injuries, damage or destruction of these support cells (glia) leads to the progressive loss of neuronal function. Q Therapeutics aims to counteract this by introducing healthy, specialized cells to the damaged sites.

The company utilizes a cell-based therapeutic approach intended to replace damaged myelin???the protective sheath around nerve fibers???and restore the normal function of neurons by providing essential support functions inherent to healthy CNS tissue. A key element of their platform is the use of progenitor cells that are "lineage-restricted," meaning they are designed to differentiate only into glia, thereby mitigating the theoretical risk of complications like uncontrolled new neuron formation or aberrant neuronal connections that could lead to issues like seizures. The therapy is designed to be administered via direct injection into the brain or spinal cord at the site of injury or disease, minimizing off-target risks often associated with systemic drug delivery. The company holds a significant intellectual property portfolio, protected by more than 20 issued patents, with additional patents pending.

Products and Services (Therapeutic Pipeline)

Q Therapeutics' primary product candidate is Q-Cells®.

Q-Cells® is a proprietary cell-based therapeutic that consists of healthy human glial-restricted progenitor cells (GRPs). GRPs are early descendants of neural stem cells capable of differentiating into various types of glia, such as astrocytes, which are crucial for maintaining neuronal health.

The company's pipeline is focused on a wide spectrum of CNS disorders, with a primary emphasis on high-unmet-need conditions:

• Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease): ALS has been the company's initial and most advanced clinical target. Q-Cells® received an Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of ALS. The product candidate received Investigational New Drug (IND) clearance from the FDA in 2015 to commence Phase 1/2a clinical trials to assess its safety and tolerability in patients with ALS. Pre-clinical data suggested that the administration of these glial cells into the brain and spinal cord could alter the course of the neurodegenerative disorder.
• Demyelinating Conditions: The regenerative mechanism of Q-Cells® is applicable to diseases where myelin is lost or damaged. These targets include:
  • Multiple Sclerosis (MS)
  • Transverse Myelitis
  • Cerebral Palsy
• Neurodegenerative Diseases and Injuries: The therapeutic approach is also being explored for other significant CNS disorders and injuries, including:
  • Spinal Cord Injury
  • Stroke
  • Traumatic Brain Injury (TBI)
  • Huntington's Disease
  • Parkinson's Disease
  • Alzheimer's Disease

The development of Q-Cells® has been supported by various sources, including grant funding from the National Institutes of Health (NIH) and a notable equity investment from Cephalon/Teva, further validating its research efforts. The company's work represents a differentiated approach in the field of neurodegenerative disease therapeutics, aiming to leverage the body's natural cellular support and repair systems to offer restorative treatments for previously incurable conditions.